Wednesday, April 20, 2016 1:19:53 PM
TransPharma based in Lod, Israel, had generated some promising buzz with its ViaDor technology, and explored its use in areas other than dermatology and cosmetic indications. The company inked a development/licensing deal with Eli Lilly ($LLY) in 2008, worth at least $35 million upfront, involving a version of Lilly's osteoporosis drug Forteo that incorporated TransPharma's delivery system technology, the business innovation news wire Israel21c reported at the time. In 2010, TransPharma successfully completed a Phase Ia trial using its then-named ViaDerm-GlP1 agonist to treat Type 2 diabetes, among other milestones.
--http://www.fiercedrugdelivery.com/drug-delivery/syneron-grabs-transpharma-assets-gains-novel-transdermal-drug-delivery-tech
This is high tech, valuable stuff we own here...
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM